AGC Biologics announced its partnership with AdaptVac. The partnership was formed to jointly develop and manufacture a COVID-19 vaccine. AdaptVac is developing a SARS-CoV-2 vaccine together with its PREVENT-nCoV consortium partners funded by the EU initiative Horizon 2020.
Q BioMed Inc., and its technology partner, Mannin Research, are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections.
